Loading clinical trials...

A Study of Paramedic HF Management | Clinical Trials | Clareo Health

RECRUITING

A Study of Paramedic HF Management

Community Paramedic Heart Failure Management (CP-HF) Program

NCT06874556•Mayo Clinic

Summary

The purpose of this research is to see if having community paramedic (CP) visit patients at home to manage their heart failure help them stay out of the hospital and improve their overall health compared to standard care. The investigators want to find out if their approach is better for patients in terms of their quality of life, hospital stays, emergency visits, and cost. The investigators are also looking to see how happy patients and doctors are with this method and if it's a practical and sustainable option for the future.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•One of the following criteria:
•1. Adults admitted to the hospital with decompensated HF eligible for early discharge with CP support and monitoring.
•2. Acutely decompensated HF patients at home or being evaluated in the ambulatory clinic who require large volume diuresis but do not require hospital-level monitoring.
•3. Stage D advanced HF patients who require frequent (\>weekly) diuretic adjustments (either inpatient or outpatients).

Exclusion Criteria

•1. Hospital-level monitoring or care is clinically indicated.
•2. Failed safety assessment, active substance abuse, or behavioral health diagnosis which could impact participation.
•3. Enrolled in hospice.
•4. Patient is a resident in a skilled nursing facility.
•5. Patient does not have a primary care physician or cardiologist at Mayo Clinic.
•6. Patient participants with communication barriers due to medical illness or cognitive impairment.
•7. Pregnant

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Key Dates

Start Date

June 24, 2025

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

July 29, 2025

Enrollment

ESTIMATED participants

Conditions

Heart Failure

Interventions

CP-HF Management

BEHAVIORAL

Contacts

Sara Biorn

CONTACT

507-266-2328 Biorn.Sara@mayo.edu

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Paramedic HF Management

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Respiratory Virus Infections in Acute Heart Failure